Table 2 Number of patients developing adverse event of infusion-related reaction 24 h after administration of sotrovimab
From: Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
Patients | (N = 139) | |
|---|---|---|
Adverse events | (%) | |
Chill/shivering | 5 | 3.6 |
Vomiting | 1 | 0.7 |
Dizziness | 1 | 0.7 |
Rash | 3 | 2.2 |
Pruritus | 2 | 1.4 |
(A) Fever > 38.0 Celsius | 33 | 23.7 |
(B) Dyspnea < 94% oximetry | 15 | 10.8 |
(A) and/or (B) | 40 | 28.8 |
Patients with any events | 44 | 31.7 |